← Oncology Approval Tracker

FDA DECISION ·

Tafinlar + Mekinist

dabrafenib plus trametinib · Novartis

Accelerated approvalNew or expanded indicationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients age six or older with BRAF V600E-mutated unresectable or metastatic solid tumors progressing after prior treatment and without satisfactory alternatives. The indication excludes colorectal cancer.

LAMPGEN ANALYSIS

Why it matters

This BRAF/MEK approval spans tumor types while retaining a colorectal exclusion.

What research teams should watch

Confirm the exact BRAF variant and tumor type and document the prior regimen and remaining alternatives.

PRIMARY RECORDS

Sources